BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol 2018;9:1821. [PMID: 30147690 DOI: 10.3389/fimmu.2018.01821] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 36.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Pandya P, Afshar S. Therapeutic Advances in Oncology. Int J Mol Sci 2021;22:2008. [PMID: 33670524 DOI: 10.3390/ijms22042008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer 2020;8:e000734. [PMID: 32661116 DOI: 10.1136/jitc-2020-000734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
3 Xu J, Nie H, He J, Wang X, Liao K, Tu L, Xiong Z. Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer. Front Oncol 2020;10:550002. [PMID: 33215029 DOI: 10.3389/fonc.2020.550002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Ahamadi-Fesharaki R, Fateh A, Vaziri F, Solgi G, Siadat SD, Mahboudi F, Rahimi-Jamnani F. Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. Mol Ther Oncolytics 2019;14:38-56. [PMID: 31011631 DOI: 10.1016/j.omto.2019.02.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
5 Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther 2021. [PMID: 33753909 DOI: 10.1038/s41434-021-00246-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
6 Bera TK. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation. Biomolecules 2020;10:E1387. [PMID: 33003418 DOI: 10.3390/biom10101387] [Reference Citation Analysis]
7 Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, Hsieh PA, Munshi N, Wahl J, Matthes K, Friedrich M, Arvedson T, Anderson KC, Tai YT. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv 2020;4:4195-207. [PMID: 32898244 DOI: 10.1182/bloodadvances.2020002524] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
8 Foureau DM, Bhutani M, Robinson M, Guo F, Pham D, Buelow B, Steuerwald N, Rigby K, Tjaden E, Leonidas M, Paul BA, Atrash S, Ndiaye A, Symanowski JT, Voorhees PM, Usmani SZ. Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma. eJHaem 2020;1:113-21. [DOI: 10.1002/jha2.69] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
9 Roex G, Feys T, Beguin Y, Kerre T, Poiré X, Lewalle P, Vandenberghe P, Bron D, Anguille S. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics 2020;12:E194. [PMID: 32102267 DOI: 10.3390/pharmaceutics12020194] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
10 DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, Startz T, Kuhnert J, Retter MW, Godin S, Sharma P, Delfino F, Lin J, Smith E, Thurston G, Kirshner JR. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv 2021;5:1291-304. [PMID: 33651100 DOI: 10.1182/bloodadvances.2020002736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncol 2019;15:1411-28. [PMID: 30816809 DOI: 10.2217/fon-2019-0013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
12 Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, Jackson NA, Ahlers CM, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, Montes de Oca R, Paul S, Holkova B, Gupta I, Kremer BE, Richardson P. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol 2021;17:1987-2003. [PMID: 33682447 DOI: 10.2217/fon-2020-1269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica 2020;105:2358-67. [PMID: 33054076 DOI: 10.3324/haematol.2020.247015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
14 Tangye SG. It's that time of year-APRIL promotes humoral immunity in humans. J Allergy Clin Immunol 2020;146:1013-5. [PMID: 32971107 DOI: 10.1016/j.jaci.2020.09.005] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther 2019;19:1143-56. [PMID: 31277554 DOI: 10.1080/14712598.2019.1641196] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
16 Lin Q, Liu X, Han L, Liu L, Fang B, Gao Q, Song Y. Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA-CAR-T therapy in patient with relapsed myeloma. Bone Marrow Transplant 2020;55:1203-5. [PMID: 31537902 DOI: 10.1038/s41409-019-0674-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, Tai YT. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers (Basel) 2020;12:E1473. [PMID: 32516895 DOI: 10.3390/cancers12061473] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
18 Serrano-Del Valle A, Anel A, Naval J, Marzo I. Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Front Cell Dev Biol 2019;7:50. [PMID: 31041312 DOI: 10.3389/fcell.2019.00050] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 27.0] [Reference Citation Analysis]
19 Soekojo CY, Ooi M, de Mel S, Chng WJ. Immunotherapy in Multiple Myeloma. Cells 2020;9:E601. [PMID: 32138182 DOI: 10.3390/cells9030601] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
20 Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, Wang D, Wang J, Jiang L, Xu H, Xu J, Zhou X, Hong Z, Wang N, Huang L, Zhang S, Chen L, Mao X, Xiao M, Zhang W, Meng L, Cao Y, Zhang T, Li J, Zhou J. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med 2021;11:e346. [PMID: 33784005 DOI: 10.1002/ctm2.346] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Corre J, Avet-Loiseau H. Risk-Based Therapeutic Strategies. Cancer J 2019;25:54-8. [PMID: 30694860 DOI: 10.1097/PPO.0000000000000352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk FA, Fehse B, Kröger N. Development of CAR-T cell therapies for multiple myeloma. Leukemia 2020;34:2317-32. [PMID: 32572190 DOI: 10.1038/s41375-020-0930-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 22.0] [Reference Citation Analysis]
23 Lightman SM, Utley A, Lee KP. Survival of Long-Lived Plasma Cells (LLPC): Piecing Together the Puzzle. Front Immunol 2019;10:965. [PMID: 31130955 DOI: 10.3389/fimmu.2019.00965] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis]
24 Grover NS, Tschernia N, Dotti G, Savoldo B. Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors. J Clin Oncol 2021;39:499-513. [PMID: 33434072 DOI: 10.1200/JCO.20.01738] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Uckun FM, Qazi S, Demirer T, Champlin RE. Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. EBioMedicine 2019;39:612-20. [PMID: 30545798 DOI: 10.1016/j.ebiom.2018.12.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
26 Wong AH, Shin EM, Tergaonkar V, Chng WJ. Targeting NF-κB Signaling for Multiple Myeloma. Cancers (Basel) 2020;12:E2203. [PMID: 32781681 DOI: 10.3390/cancers12082203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
27 Rader C. Bispecific antibodies in cancer immunotherapy. Curr Opin Biotechnol 2020;65:9-16. [PMID: 31841859 DOI: 10.1016/j.copbio.2019.11.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
28 Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Front Immunol 2019;10:1613. [PMID: 31379824 DOI: 10.3389/fimmu.2019.01613] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 19.5] [Reference Citation Analysis]
29 Popat R, Warcel D, O'Nions J, Cowley A, Smith S, Tucker WR, Yong K, Esposti SD. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica 2020;105:e261-3. [PMID: 32107339 DOI: 10.3324/haematol.2019.235937] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 22.0] [Reference Citation Analysis]
30 Abramson HN. Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther 2021;10:343-71. [PMID: 34527606 DOI: 10.2147/ITT.S306103] [Reference Citation Analysis]
31 Meng L, Tang Q, Zhao J, Wang Z, Wei L, Wei Q, Yin L, Luo S, Song J. S100A9 Derived From Myeloma Associated Myeloid Cells Promotes TNFSF13B/TNFRSF13B-Dependent Proliferation and Survival of Myeloma Cells. Front Oncol 2021;11:691705. [PMID: 34150664 DOI: 10.3389/fonc.2021.691705] [Reference Citation Analysis]
32 Oriol A, Abril L, Torrent A, Ibarra G, Ribera JM. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Ther Adv Hematol 2021;12:20406207211019622. [PMID: 34104374 DOI: 10.1177/20406207211019622] [Reference Citation Analysis]
33 Xing L, Lin L, Yu T, Li Y, Cho SF, Liu J, Wen K, Hsieh PA, Kinneer K, Munshi N, Anderson KC, Tai YT. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia 2020;34:2150-62. [PMID: 32060401 DOI: 10.1038/s41375-020-0745-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
34 van der Schans JJ, van de Donk NWCJ, Mutis T. Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. Front Oncol 2020;10:1362. [PMID: 32850436 DOI: 10.3389/fonc.2020.01362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
35 Mikhael J. Treatment Options for Triple-class Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 2020;20:1-7. [DOI: 10.1016/j.clml.2019.09.621] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 20.0] [Reference Citation Analysis]
36 Choi T, Kang Y. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. Pharmacol Ther 2021;:108007. [PMID: 34582835 DOI: 10.1016/j.pharmthera.2021.108007] [Reference Citation Analysis]
37 Dempsey JL, Johns A, Rosko AE, Lazarus HM. The pharmacologic management of multiple myeloma in older adults. Expert Opin Pharmacother 2019;20:887-902. [PMID: 30785310 DOI: 10.1080/14656566.2019.1577822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Wang Q, He F, He W, Huang Y, Zeng J, Zi F, Zheng J, Fei Y, Xu J, Song Y, Ye X, Lai R, Ye L, Zhu B. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. Cell Immunol 2021;363:104342. [PMID: 33765541 DOI: 10.1016/j.cellimm.2021.104342] [Reference Citation Analysis]
39 Walker BA, Morgan GJ. The genomic features associated with high-risk multiple myeloma. Oncotarget 2018;9:35478-9. [PMID: 30464803 DOI: 10.18632/oncotarget.26269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Baert L, Manfroi B, Casez O, Sturm N, Huard B. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting. Journal of Autoimmunity 2018;95:179-90. [DOI: 10.1016/j.jaut.2018.10.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
41 García-Guerrero E, Sierro-Martínez B, Pérez-Simón JA. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. Front Immunol 2020;11:1128. [PMID: 32582204 DOI: 10.3389/fimmu.2020.01128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
42 Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34:985-1005. [PMID: 32055000 DOI: 10.1038/s41375-020-0734-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 72.0] [Reference Citation Analysis]
43 Feng D, Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Scand J Immunol 2020;92:e12910. [PMID: 32471019 DOI: 10.1111/sji.12910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
44 Rustad EH, Yellapantula VD, Glodzik D, Maclachlan KH, Diamond B, Boyle EM, Ashby C, Blaney P, Gundem G, Hultcrantz M, Leongamornlert D, Angelopoulos N, Agnelli L, Auclair D, Zhang Y, Dogan A, Bolli N, Papaemmanuil E, Anderson KC, Moreau P, Avet-Loiseau H, Munshi NC, Keats JJ, Campbell PJ, Morgan GJ, Landgren O, Maura F. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov 2020;1:258-73. [PMID: 33392515 DOI: 10.1158/2643-3230.bcd-20-0132] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 19.0] [Reference Citation Analysis]
45 Shancer Z, Liu XF, Nagata S, Zhou Q, Bera TK, Pastan I. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. Proc Natl Acad Sci U S A 2019;116:4592-8. [PMID: 30782819 DOI: 10.1073/pnas.1821733116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
46 Lin L, Cho SF, Xing L, Wen K, Li Y, Yu T, Hsieh PA, Chen H, Kurtoglu M, Zhang Y, Andrew Stewart C, Munshi N, Anderson KC, Tai YT. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 2021;35:752-63. [PMID: 32632095 DOI: 10.1038/s41375-020-0951-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
47 Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv 2020;4:2899-911. [PMID: 32589729 DOI: 10.1182/bloodadvances.2019001346] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
48 Mateos MV, Bladé J, Bringhen S, Ocio EM, Efebera Y, Pour L, Gay F, Sonneveld P, Gullbo J, Richardson PG. Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. J Clin Med 2020;9:E3120. [PMID: 32992506 DOI: 10.3390/jcm9103120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
49 Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res 2020;26:6028-38. [PMID: 32917735 DOI: 10.1158/1078-0432.CCR-20-0400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf JL, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics 2020;10:2645-58. [PMID: 32194826 DOI: 10.7150/thno.38533] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
51 Lernoux M, Schnekenburger M, Dicato M, Diederich M. Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors. Biochem Pharmacol 2021;188:114526. [PMID: 33741332 DOI: 10.1016/j.bcp.2021.114526] [Reference Citation Analysis]
52 Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to Treat High-Risk Myeloma at Diagnosis and Relapse. Am Soc Clin Oncol Educ Book 2021;41:291-309. [PMID: 34010042 DOI: 10.1200/EDBK_320105] [Reference Citation Analysis]
53 Nishida H, Yamada T. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets. J Oncol 2019;2019:6084012. [PMID: 31781214 DOI: 10.1155/2019/6084012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
54 Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Chinen Y, Tanba K, Kuwahara-Ota S, Fujibayashi Y, Nishiyama D, Isa R, Yamaguchi J, Kawaji-Kanayama Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma. Cancer Med 2020;9:5185-99. [PMID: 32420699 DOI: 10.1002/cam4.3136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Dogan A, Siegel D, Tran N, Fu A, Fowler J, Belani R, Landgren O. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J 2020;10:73. [PMID: 32606424 DOI: 10.1038/s41408-020-0337-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
56 Yurkovich JT, Tian Q, Price ND, Hood L. A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Nat Rev Clin Oncol 2020;17:183-94. [DOI: 10.1038/s41571-019-0273-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
57 Sanoja-Flores L, Flores-Montero J, Pérez-Andrés M, Puig N, Orfao A. Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications. Cancers (Basel) 2020;12:E1499. [PMID: 32521788 DOI: 10.3390/cancers12061499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
58 Mahler MR, Søndergaard HB, Buhelt S, von Essen MR, Romme Christensen J, Enevold C, Sellebjerg F. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. Multiple Sclerosis and Related Disorders 2020;45:102391. [DOI: 10.1016/j.msard.2020.102391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
59 Andrews JM, Schmidt JA, Carson KR, Musiek AC, Mehta-Shah N, Payton JE. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. EBioMedicine 2019;46:170-83. [PMID: 31358475 DOI: 10.1016/j.ebiom.2019.07.053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
60 Chames P, Wurch T. [Bispecific antibodies, novel therapeutic candidates harnessing the immune system]. Med Sci (Paris) 2019;35:1072-82. [PMID: 31903920 DOI: 10.1051/medsci/2019242] [Reference Citation Analysis]
61 Holthof LC, Mutis T. Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance. Cancers (Basel) 2020;12:E988. [PMID: 32316450 DOI: 10.3390/cancers12040988] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
62 Nicolini F, Bravaccini S, Mazza M, Gruszka AM, Tazzari M, MartÍn-Antonio B, Juan M, Ibrahim T, Maltoni R, Martinelli G, Cerchione C. CAR T cells targeting options in the fight against multiple myeloma. Panminerva Med 2021;63:37-45. [PMID: 32955187 DOI: 10.23736/S0031-0808.20.04146-4] [Reference Citation Analysis]
63 Geis M, Nowotny B, Bohn MD, Kouhestani D, Einsele H, Bumm T, Stuhler G. Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. Commun Biol 2021;4:44. [PMID: 33420283 DOI: 10.1038/s42003-020-01558-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 Utley A, Lipchick B, Lee KP, Nikiforov MA. Targeting Multiple Myeloma through the Biology of Long-Lived Plasma Cells. Cancers (Basel) 2020;12:E2117. [PMID: 32751699 DOI: 10.3390/cancers12082117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Liu D. Cancer biomarkers for targeted therapy. Biomark Res 2019;7:25. [PMID: 31807308 DOI: 10.1186/s40364-019-0178-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
66 Gambella A, Barreca A, Osella-Abate S, Bottasso E, Giarin MM, Papotti M, Biancone L, Metovic J, Collemi G, Cassoni P, Bertero L. Caveolin-1 in Kidney Chronic Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel. Biomedicines 2021;9:1318. [PMID: 34680435 DOI: 10.3390/biomedicines9101318] [Reference Citation Analysis]
67 Feinberg D, Paul B, Kang Y. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cell Immunol 2019;345:103964. [PMID: 31492448 DOI: 10.1016/j.cellimm.2019.103964] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
68 Yamamoto L, Amodio N, Gulla A, Anderson KC. Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Front Oncol 2020;10:606368. [PMID: 33585226 DOI: 10.3389/fonc.2020.606368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
69 Nelke J, Medler J, Weisenberger D, Beilhack A, Wajant H. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism. MAbs 2020;12:1807721. [PMID: 32840410 DOI: 10.1080/19420862.2020.1807721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Braunstein M, Weltz J, Davies F. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma. Expert Rev Hematol 2021;14:377-89. [PMID: 33769179 DOI: 10.1080/17474086.2021.1909469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Nishida H. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers (Basel) 2021;13:2712. [PMID: 34072645 DOI: 10.3390/cancers13112712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Cho SF, Anderson KC, Tai YT. BCMA CAR T-cell therapy arrives for multiple myeloma: a reality. Ann Transl Med 2018;6:S93. [PMID: 30740414 DOI: 10.21037/atm.2018.11.14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
73 Romano A, Storti P, Marchica V, Scandura G, Notarfranchi L, Craviotto L, Di Raimondo F, Giuliani N. Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. Front Oncol 2021;11:684561. [PMID: 34307150 DOI: 10.3389/fonc.2021.684561] [Reference Citation Analysis]
74 Shah UA, Mailankody S. CAR T and CAR NK cells in multiple myeloma: Expanding the targets. Best Pract Res Clin Haematol 2020;33:101141. [PMID: 32139020 DOI: 10.1016/j.beha.2020.101141] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
75 Hanna KS, Larson S, Nguyen J, Tu S, Boudreau J, Rose S. Updates in the management of relapsed/refractory multiple myeloma. J Oncol Pharm Pract 2021;:10781552211028906. [PMID: 34162244 DOI: 10.1177/10781552211028906] [Reference Citation Analysis]
76 Tamma R, Ranieri G, Ingravallo G, Annese T, Oranger A, Gaudio F, Musto P, Specchia G, Ribatti D. Inflammatory Cells in Diffuse Large B Cell Lymphoma. J Clin Med 2020;9:E2418. [PMID: 32731512 DOI: 10.3390/jcm9082418] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
77 Bath NM, Ding X, Verhoven BM, Wilson NA, Coons L, Sukhwal A, Zhong W, Redfield Iii RR. Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model. PLoS One 2019;14:e0223889. [PMID: 31647850 DOI: 10.1371/journal.pone.0223889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
78 Abramson HN. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int J Mol Sci 2018;19:E3924. [PMID: 30544512 DOI: 10.3390/ijms19123924] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
79 Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021;18:71-84. [PMID: 32978608 DOI: 10.1038/s41571-020-0427-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 26.0] [Reference Citation Analysis]
80 Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, Loeffelholz T, Wolf CR, Taylor JJ, Gardner RA, Green DJ, Cowan AJ, Maloney DG, Turtle CJ, Pergam SA, Chu HY, Bloom JD, Hill JA. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy. medRxiv 2021:2021. [PMID: 34013294 DOI: 10.1101/2021.05.10.21256634] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 2020;13:125. [PMID: 32943087 DOI: 10.1186/s13045-020-00962-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
82 Li Z, Song W, Rubinstein M, Liu D. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol 2018;11:142. [PMID: 30577797 DOI: 10.1186/s13045-018-0684-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 19.3] [Reference Citation Analysis]
83 Oriol A, Abril L, Ibarra G, Senin A. Limited treatment options in refractory multiple myeloma: promising therapeutic developments. Expert Rev Anticancer Ther 2020;20:31-44. [PMID: 31865804 DOI: 10.1080/14737140.2020.1708721] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
84 Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F, Anguille S. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol 2020;13:164. [PMID: 33272302 DOI: 10.1186/s13045-020-01001-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
85 Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. Clin Cancer Res 2020;26:1541-54. [PMID: 31672768 DOI: 10.1158/1078-0432.CCR-19-2111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
86 Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ 2020;370:m3176. [PMID: 32958461 DOI: 10.1136/bmj.m3176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
87 Wang Y, Li H, Xu W, Pan M, Qiao C, Cai J, Xu J, Wang M, Zhang J. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma. Journal of Immunotherapy 2020;43:175-88. [DOI: 10.1097/cji.0000000000000320] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
88 Atabaki M, Shariati-sarabi Z, Tavakkol-afshari J, Mohammadi M. Significant immunomodulatory properties of curcumin in patients with osteoarthritis; a successful clinical trial in Iran. International Immunopharmacology 2020;85:106607. [DOI: 10.1016/j.intimp.2020.106607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
89 Nowacka KH, Jabłońska E. Role of the APRIL molecule in solid tumors. Cytokine Growth Factor Rev 2021;61:38-44. [PMID: 34446365 DOI: 10.1016/j.cytogfr.2021.08.001] [Reference Citation Analysis]
90 Wang Y, Luong M, Guadiz C, Zhang M, Gorovits B. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody. J Immunol Methods 2019;474:112642. [PMID: 31400410 DOI: 10.1016/j.jim.2019.112642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 D'Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia 2020;34:21-34. [PMID: 31780814 DOI: 10.1038/s41375-019-0669-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 27.5] [Reference Citation Analysis]
92 Hagen PA, Stiff P. The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation 2019;25:e98-e107. [DOI: 10.1016/j.bbmt.2018.12.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
93 Szalat R, Munshi NC. Novel Agents in Multiple Myeloma. Cancer J 2019;25:45-53. [PMID: 30694859 DOI: 10.1097/PPO.0000000000000355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
94 Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and Targeted Approaches in Multiple Myeloma. Immunotargets Ther 2020;9:201-15. [PMID: 33117743 DOI: 10.2147/ITT.S240886] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
95 Alhallak K, Sun J, Jeske A, Park C, Yavner J, Bash H, Lubben B, Adebayo O, Khaskiah A, Azab AK. Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. Cancers (Basel) 2021;13:2853. [PMID: 34201007 DOI: 10.3390/cancers13122853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Strassl I, Schreder M, Steiner N, Rudzki J, Agis H, Künz T, Müser N, Willenbacher W, Petzer A, Neumeister P, Krauth MT. The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. Cancers (Basel) 2021;13:4701. [PMID: 34572927 DOI: 10.3390/cancers13184701] [Reference Citation Analysis]
97 Jiao Y, Yi M, Xu L, Chu Q, Yan Y, Luo S, Wu K. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. Expert Opin Investig Drugs 2020;29:1295-308. [PMID: 32822558 DOI: 10.1080/13543784.2020.1814253] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
98 Rodríguez-Otero P, Prósper F, Alfonso A, Paiva B, San Miguel JF. CAR T-Cells in Multiple Myeloma Are Ready for Prime Time. J Clin Med 2020;9:E3577. [PMID: 33172026 DOI: 10.3390/jcm9113577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
99 Abramson HN. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci 2020;21:E5192. [PMID: 32707894 DOI: 10.3390/ijms21155192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
100 Caraccio C, Krishna S, Phillips DJ, Schürch CM. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions. Front Immunol 2020;11:501. [PMID: 32391000 DOI: 10.3389/fimmu.2020.00501] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 30.0] [Reference Citation Analysis]
101 Wudhikarn K, Wills B, Lesokhin AM. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action. Best Pract Res Clin Haematol 2020;33:101143. [PMID: 32139009 DOI: 10.1016/j.beha.2020.101143] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
102 Shah UA, Smith EL. Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells. Cancer J 2019;25:208-16. [DOI: 10.1097/ppo.0000000000000379] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]